Serife Ezgi Dogan

Dr. Serife Ezgi Dogan

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Transplantation Proceedings
Verified
Journal Article
Closed access
SDSerife Ezgi Dogan
Serife Ezgi Dogan
ZCZ.K. Celebi
Z.K. Celebi
SAS. Akturk
S. Akturk
SKS. Kutlay
S. Kutlay
ATA. Tuzuner
A. Tuzuner
SSS. Sengul
S. Sengul

18 February 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
SDSerife Ezgi Dogan
Serife Ezgi Dogan
ŞKŞeri̇fE Mehli̇kA Kuşkonmaz
Şeri̇fE Mehli̇kA Kuşkonmaz
PCPinar Celepli̇
Pinar Celepli̇
MŞMehmet Şenes
Mehmet Şenes
SHSema Hücümenoğlu
Sema Hücümenoğlu
CÇCavi̇t Çulha
Cavi̇t Çulha
Background/aim: The objective of this study is to evaluate the effect of empagliflozin on cyclophosphamide-induced neurotoxicity in rats.Materials and methods: A total of 32 male Wistar rats were separated into 4 groups as 8 rats each: control group, cyclophosphamide group, empagliflozin group and the cyclophosphamide plus empagliflozin group. At the end of the experiment rats' brains were removed for biochemical analysis of oxidative stress parameters (malondialdehyde, total sulfhydryl, total oxidant status and total antioxidant capacity) and histopathological analysis.Results: Total sulfhydryl levels were increased in group empagliflozin and group empagliflozin and cyclophosphamide compared to the cyclophosphamide group but did not improve histopathological findings. Furthermore, when empagliflozin treatment was used coupled with cyclophosphamide, necrosis was significantly higher. Conclusion: In conclusion, empagliflozin has no protective effect on cyclophosphamide neurotoxicity in addition it may have neurotoxic effects. Clarification of possible neurotoxic/neuroprotective effects of empagliflozin would be beneficial for diabetic cancer patients who are receiving cyclophosphamide chemotherapy and empagliflozin together.

16 February 2026 in Archives of Osteoporosis
Verified
Journal Article
Open access
PDF file
OGOzen Oz Öz Gul
Ozen Oz Öz Gul
ZCZeynep Cantürk
Zeynep Cantürk
SOSaadettin Ozturk
Saadettin Ozturk
NONilufer Ozdemir
Nilufer Ozdemir
DCDilek Kılınç Candemir
Dilek Kılınç Candemir
GOGuven Ozkaya
Guven Ozkaya
Summary: We assessed bone health in over 2500 adults with diabetes across Türkiye. T1DM patients had lower BMD, while T2DM patients showed higher fracture risk despite higher BMD. Several modifiable factors were linked to osteoporosis. These findings support personalized bone assessments in diabetic populations. Background: Diabetes mellitus (DM) is a recognized risk factor for bone fragility. While type 1 DM (T1DM) is typically associated with low bone mineral density (BMD), type 2 DM (T2DM) often presents with higher BMD despite increased fracture risk. Large-scale comparative studies remain limited. Objective: To evaluate bone health, including osteopenia, osteoporosis, and fracture risk, in adults with T1DM and T2DM. Methods: This multicenter, cross-sectional study included 2562 patients (224 with T1DM, 2338 with T2DM) from 27 centers across Türkiye. BMD was assessed using dual-energy X-ray absorptiometry (DXA) and fracture risk was estimated via the Turkish-adapted FRAX® algorithm in patients aged ≥ 40 years. Multinomial logistic regression was used to identify independent predictors of low BMD. Results: Osteoporosis prevalence was 5.5% in T1DM and 9.6% in T2DM (femoral neck T-score). Adjusted BMD was significantly lower in T1DM at all skeletal sites, while FRAX-based fracture risk and fall-related fractures were higher in T2DM. Independent predictors of osteoporosis included older age, female sex, lower BMI, reduced calcium levels, corticosteroid use, albuminuria, hypertension, and less frequent sodium-glucose cotransporter-2 (SGLT2) inhibitor use. T1DM was independently associated with osteopenia but not osteoporosis. Conclusion: This multicenter study demonstrates distinct patterns of BMD and fracture risk across diabetes subtypes and supports individualized bone health assessment in routine diabetes care.

2 May 2023 in Endocrine Abstracts
Verified
Journal Article
Closed access
SDSerife Ezgi Dogan
Serife Ezgi Dogan
SKSerife Mehlika Kuskonmaz
Serife Mehlika Kuskonmaz
GKGonul Koc
Gonul Koc
TOTulay Omma
Tulay Omma
SFSevde Nur Firat
Sevde Nur Firat
CCCavit Culha
Cavit Culha
Diabetes is one of the risk factors for Achilles tendon rupture. Tendon thickening and impaired collagen organization have been reported in diabetic patients in small studies. In this report, we present the rupture of the Achilles tendon in a female patient with poorly controlled diabetes mellitus and diabetic neuropathy. A 52-years-old woman with a medical history of diabetes treated by intensive insulin therapy, developed pain in the right heel without previous trauma. The patient applied to the hospital because of the inability to walk for the last 5 days. Spontaneous rupture of the right Achilles tendon was diagnosed with MRI. Primary repair of achilles tendon planned. Diabetic ketosis treatment was performed due to preoperative blood sugar being 550 mg/dl and urine ketone positive. Afterwards, the tendon was treated by suture. Chronic hyperglycemia affects the Achilles tendon as well as many organs. Degenerative changes were more common in men and those with peripheral neuropathy. Although the risk of Achilles tendon rupture was more common in those with uncontrolled diabetes and female gender. Systemic approach is important in the follow-up of diabetic patients and heel pain should be evaluated in terms of Achilles tendon rupture, apart from diabetic neuropathy and diabetic foot.

31 July 2026 in Northwestern Medical Journal
Verified
Journal Article
Open access
PDF file
PGPüren Gökbulut
Püren Gökbulut
SDSerife Ezgi Dogan
Serife Ezgi Dogan
ÇÖÇağatay Emir Önder
Çağatay Emir Önder
ITIşılay Taşkaldıran
Işılay Taşkaldıran
CÇCavit Çulha
Cavit Çulha
TOTülay Omma
Tülay Omma
Objective: To evaluate cognitive performance in patients with chronic postoperative hypoparathyroidism and to investigate its association with biochemical parameters.Methods: This prospective, observational, cross-sectional study included 56 patients aged 40–65 years with chronic postoperative hypoparathyroidism, 28 post-thyroidectomy hypothyroid patients without hypoparathyroidism, and 28 healthy controls. Cognitive function was assessed using the Mini-Mental State Examination (MMSE). Biochemical parameters, including albumin-corrected serum calcium and intact parathyroid hormone (iPTH), were measured concurrently. Multivariable analyses were performed to identify independent determinants of cognitive performance.Results: Although no significant differences were observed among the groups in terms of total MMSE scores, selective differences were detected in the registration and language subdomains in patients with chronic postoperative hypoparathyroidism. Albumin-corrected serum calcium levels and age independently predicted language performance. In addition, a positive correlation was identified between iPTH levels and registration memory scores.Conclusion: Chronic postoperative hypoparathyroidism may be associated with mild, domain-specific cognitive alterations rather than global cognitive decline. The association of albumin-corrected serum calcium and age with language performance suggests a potential role of calcium homeostasis in cognitive function. Cognitive assessment may therefore be considered as part of long-term follow-up in these patients.

15 August 2026 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
BGBağdagül Yüksel Güler
Bağdagül Yüksel Güler
MEMehdi Erdem
Mehdi Erdem
MDMuzaffer Serdar Deniz
Muzaffer Serdar Deniz
SYSafiye Kızışar Yılmaz
Safiye Kızışar Yılmaz
SDSerife Ezgi Dogan
Serife Ezgi Dogan
Aims: Subacute thyroiditis (SAT) is a self-limiting inflammatory thyroid disorder that frequently presents with neck pain, systemic symptoms, and biochemical thyrotoxicosis. Delayed recognition of SAT may lead to repeated healthcare visits, inappropriate antibiotic use, and postponement of appropriate treatment. This study aimed to evaluate healthcare-seeking behavior, referral patterns, antibiotic use, and treatment approaches among patients diagnosed with SAT at a tertiary referral center. Additionally, demographic characteristics of patients diagnosed during the study period were assessed. Methods: In this retrospective cross-sectional study, medical records of patients evaluated for SAT in the Endocrinology Department of Sincan Training and Research Hospital between June 2023 and March 2025 were reviewed. Among 117 identified cases, 100 patients with confirmed SAT and complete clinical data were included in the analysis. Demographic characteristics, departments visited before endocrinology referral, time from symptom onset to endocrinology evaluation, antibiotic use, laboratory findings, thyroid ultrasonography results, and treatment methods were analyzed. Results: The study population consisted predominantly of female (74%), with a mean age of 45.4±9.9 years. The mean interval between symptom onset and endocrinology referral was 23.7±17.3 days. Prior to endocrinology evaluation, patients most frequently presented to internal medicine (45.6%) and otorhinolaryngology (14.4%) clinics. Notably, some patients sought care from multiple specialties, including emergency departments. Elevated inflammatory markers were observed at presentation, with mean erythrocyte sedimentation rate and C-reactive protein levels of 52.7±30.8 mm/h and 7.9±18.0 mg/dl, respectively. Before receiving a diagnosis of SAT, 42% of patients had been prescribed antibiotics, most commonly cephalosporins and amoxicillinclavulanate. Typical ultrasonographic findings of SAT were present in 80% of patients. Following diagnosis, the most frequently prescribed treatment regimen was a combination of nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (42%), followed by NSAID monotherapy (27%) and corticosteroid monotherapy (26%). Conclusion: A substantial proportion of patients with SAT underwent evaluation by multiple healthcare providers and received unnecessary antibiotic treatment before referral to endocrinology services. These findings underscore the continuing challenges in early recognition of SAT and the importance of increasing clinical awareness, particularly among first-contact healthcare providers. Earlier identification of SAT may reduce diagnostic delays, minimize inappropriate antibiotic use, and facilitate timely initiation of appropriate therapy.